AirNexis

Drug Discovery · Biotechnology
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Explore the future of inhaled therapy for COPD with AirNexis's innovative AN01 dry powder inhaler designed for ease of use.

Website
airnexis.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Newsroom

Sep 82026
Blog
The post AirNexis Announces that AN01 Met its Primary Endpoint in a Phase 2b COPD Study appeared first on AirNexis.
Jan 122026
News · news.qq.com
近日海思科宣布与美国AirNexis公司签订独占许可协议授予后者在除中国大陆、中国香港特别行政区、中国澳门特别行政区及中国台湾地区以外的全球范围内开发、生产和商业化HSK39004的独家权利根据协议AirNexis将向海思科支付1.08亿美元首付款(含4000万美元现金及等值约6800万美元的AirNexis公司19.9%股权)以及最高9....
Jan 112026
News · Pulse 2.0
AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license t…
Jan 102026
News · finance.sina.com.cn
1月9日晚间海思科公告称公司与美国AirNexis Therapeutics, Inc.AirNexis签订独占许可协议授予AirNexis在除中国以外的全球范围内开发、生产和商业化HSK39004的独家权利本次交易构成共同投资...
Jan 92026
News · news.qq.com
每经AI快讯1月9日海思科公告称公司与美国AirNexis Therapeutics, Inc.签订独占许可协议授予AirNexis在除中国大陆、香港、澳门及台湾地区以外的全球范围内开发、生产和商业化HSK39004的独家权利AirNexis将向海思科支付1.08亿美元首付款含4000万美元现金及等值约6800万美元的AirNexis公司19.9%股权及…
Sources: the outlets named on each headline, each story once